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Nanomaterials of porous silicon have attracted intense interest for imaging and treatment of diseases including cancer due to their biocompatibility, large specifi c capacity for drug loading, non-toxic degradation products, and effi cient photoluminescence. [1] [2] [3] [4] [5] [6] [7] [8] [9] One of the main barriers to any nanoparticle intended for in vivo use is the surveillance by the immune system. [10] [11] [12] For example, the mononuclear phagocyte system (MPS) recognizes and intercepts substantial quantities of systemically administered nanoparticles before they can reach the diseased tissues, [11] [12] [13] and this can lead to significant damage to major organs such as liver, spleen, etc., especially when the nanomaterials carry lethal anticancer drugs. In contrast, approaches to intentionally activate the body's own immune system to fi ght against diseases can be quite effective. [14] [15] [16] [17] [18] [19] [20] The goal of active immunotherapy is to elicit or amplify an immune response to harness the body's inherent defenses against foreign pathogens and self-malignancy. The experimental use of nanomaterials for such active immunotherapies has not been explored to a great extent in part due to the limited understanding of the interactions between the immune system and nanomaterials. [ 21 ] Nevertheless, recent studies have shown that some nanoparticle-based vaccines can be much more potent than soluble peptide or protein antigens, [22] [23] [24] [25] [26] [27] [28] [29] [30] and it has been proposed that nanovaccines are more adaptable and perhaps safer than viral vaccines. [31] [32] [33] Most studies using nanomaterials in immunotherapies focus on antigen delivery, with little emphasis on the ability of nanomaterials to alter the potency of immunomodulators. In addition, the majority of nanovaccine systems are based on lipids or polymers such as poly(lactic-co-glycolic acid) (PLGA), or polystyrene, [ 23 , 24 , 34-39 ] many of which display some intrinsic immune stimulation that may limit their use for immunotherapies (due to unintended stimulation of APCs) or that may interfere with the function of loaded immunomodulators. For many immunotherapeutic or immunomodulation applications, a desirable criterion is that the nanomaterial itself shows low intrinsic immune stimulation.
CD40 is a co-stimulatory receptor as well as a member of the family of tumor necrosis factor (TNF) receptors found on APCs such as dendritic cells, B cells, and macrophages. [40] [41] [42] Agonistic monoclonal antibodies to CD40 (CD40 mAb) can activate APCs and improve immune responses when used in combination with antigens or vaccines. [ 18 , 43 , 44 ] In addition, CD40 mAb can produce substantial antitumor effi cacy and can also potentially be used to treat chronic autoimmune infl ammation. [45] [46] [47] [48] However, the therapeutically effective dose of CD40 mAb is high and the high dose can result in severe side effects. [ 47 , 49 ] We have developed nanoparticles based on luminescent porous silicon that display low systemic toxicity and degrade in vivo into renally cleared components. [ 1 , 50 , 51 ] The porous nanostructure One of the fundamental paradigms in the use of nanoparticles to treat disease is to evade or suppress the immune system in order to minimize systemic side effects and deliver suffi cient nanoparticle quantities to the intended tissues. However, the immune system is the body's most important and effective defense against diseases. It protects the host by identifying and eliminating foreign pathogens as well as self-malignancies. Here we report a nanoparticle engineered to work with the immune system, enhancing the intended activation of antigen presenting cells (APCs). We show that luminescent porous silicon nanoparticles (LPSiNPs), each containing multiple copies of an agonistic antibody (FGK45) to the APC receptor CD40, greatly enhance activation of B cells. The cellular response to the nanoparticle-based stimulators is equivalent to a 30-40 fold larger concentration of free FGK45. The intrinsic near-infrared photoluminescence of LPSiNPs is used to monitor degradation and track the nanoparticles inside APCs.
and intrinsic near-infrared photoluminescence of porous silicon nanoparticles (LPSiNPs) enable the incorporation of drug payloads and the monitoring of distribution and degradation in vivo. [ 1 ] In this study, we show that when multiple copies of agonistic CD40 mAb (clone FGK45) are incorporated onto a LPSiNP, the activation potency on B cells is signifi cantly amplifi ed, equivalent to using ∼ 30-40 fold larger concentration of free FGK45. LPSiNPs without FGK45 appear inert to B cells.
LPSiNPs were prepared by electrochemical etch of highly doped p-type single-crystal Si wafers in an electrolyte consisting of aqueous hydrofl uoric acid and ethanol, lift-off of the porous layer, ultrasonic fracture, fi ltration of the resulting nanoparticles through a 0.22 μ m fi lter membrane, and fi nally activation of luminescence by treatment in an aqueous solution following the published procedure. [ 1 , 51 ] To incorporate FGK45 onto the nanoparticles, we fi rst coated the LPSiNPs with avidin by physisorption (av-LPSiNPs). Biotinylated FGK45 was then conjugated to the nanoparticles through the strong biotin-avidin binding interaction (FGK-LPSiNPs), Figure 1 a. Approximately 0.058 mg of FGK45 was loaded per milligram of LPSiNPs, as measured by bicinchoninic acid (BCA) protein assay. The presence of FGK45 loaded on nanoparticle-FGK45 construct was also confi rmed by gel electrophoresis and immunoblotting ( Figure S1 , Supporting Information). The FGK-LPSiNPs appeared similar to LPSiNPs in the transmission electron microscope (TEM) images (Figure 1 b) , but the mean hydrodynamic size measured by dynamic light scattering (DLS) increased from ∼ 130 ± 10 nm to ∼ 188 ± 15 nm after protein attachment ( Figure S2 , Supporting Information).
The intrinsic photoluminescence from the silicon nanostructures in FGK-LPSiNPs under ultraviolet excitation appeared in the near-infrared region of the spectrum ( λ max = 790 nm), similar to the non-loaded LPSiNPs. However, the intensity of photoluminescence was somewhat lower from the proteincoated formulation (Figure 1 c) . [ 1 ] In a physiologically relevant aqueous solution of phosphate buffered saline (PBS) at pH 7.4 and 37 ° C, the FGK-LPSiNP construct was observed to degrade by 95% within 24 h (Figure 1 d) . The degradation was tracked by monitoring disappearance of the photoluminescence signal, which decreased gradually upon dissolution of the quantum confi ned silicon nanostructure, [ 7 , 52 ] and by appearance of free silicic acid in solution (by inductively coupled plasma-optical emission spectroscopy, ICP-OES), Figure 1 It has been shown that the CD40 ligand and agonistic antibodies can induce endocytosis of CD40 upon binding, [ 53 , 54 ] which may be responsible for cellular uptake of FGK-LPSiNP in the present case. However, because agonistic CD40 antibodies can also engage Fc γ RIIB on APCs, [ 55 ] interaction of cellular receptors for the Fc domain of the FGK45 antibody could also contribute to the uptake. We tested for inhibition of this interaction by pre-incubation of BMDC with anti-mouse Fc γ RII-III. The presence of Fc γ RII-III somewhat reduced, but did not eliminate, cellular uptake of FGK-LPSiNP After 42 h of culture, the FITC signal was only detected from B cells that had been exposed to FGK-LPSiNPs (Figure 3 b-e) . B cells incubated with FGK-LPSiNPs also displayed increased expression of the cell surface receptors, CD86 and major histocompatibility complex class II (MHC II), the response typical of B cells that have received a signal through CD40 (Figure 3 b-e). [ 45 ] Furthermore, the extent of activation induced by FGK-LPSiNPs was concentration dependent ( Figure S5 , Supporting Information). When exposed to a low concentration of FGK-LPSiNPs, not all of the B cells were activated, as indicated by the wide distribution of the fl uorescence intensity from the cells in fl ow cytometry dot plots (Figure 3 b, 3 d) . However, the population of B cells that displayed high FITC signals also expressed high levels of CD86 and MHC II, indicating that the cells bound with nanoparticles were the ones that were activated (Figure 3 b, 3 d) . In contrast, B cells cultured with various concentrations of avLPSiNP all showed low FITC signals and low activation marker levels ( Figure S5 , Supporting Information).
Multivalency is one of the notable advantages of using nanomaterials for biomedical applications. For example, studies using nanoparticles as cancer diagnostic and therapeutic agents have shown that when multiple copies of tumor targeting ligand are displayed on an individual nanoparticle, its tumor targeting effi ciency can be signifi cantly enhanced. [60] [61] [62] [63] This enhancement is generally ascribed to the multivalent effect which is also observed in many natural processes such as antibody interactions and clotting. [ 11 ] To determine if multivalency plays a strong role in the activation potency of the agonistic antibody to APCs, we cultured B cells with either FGK-LPSiNPs or an equivalent concentration of free FGK45 and analyzed the cells by fl ow cytometry. Both FGK-LPSiNPs and free FGK45 activated B cells, and the activation level of the cells correlated with ( Figure S3 , Supporting Information), which suggests that this is a relevant (but not exclusive) internalization element in the present system. Subcellular localization of FGK-LPSiNPs was further examined by confocal fl uorescence microscopy. By following the near-infrared photoluminescence spectrum of the nanoparticles, we observed FGK-LPSiNPs outside of the lysosomes of the dendritic cells (Figure 2 d and Supporting Information, Video S1). The appearance of FGK-LPSiNPs outside of the lysosomes of the dendritic cells is consistent with previous reports that various types of silicon or silica based nanomaterials can escape from lysosomes and distribute inside the cytosol. [ 1 , 56-58 ] In separate experiments aimed at simulating the low pH conditions inside the lysosome, only < 5% dissolution of LPSiNPs was observed in pH 4 buffer solution over a 24 h period ( Figure 2 e and Supporting Information, Figure S4 ). Although LPSiNPs are expected to degrade within a few hours at pH 7.4 due to dissolution of the protective oxide coating, [ 1 , 59 ] they are much more stable in acidic media such as the environment present in the interior of lysosomes. The observed ability of LPSiNPs to escape from lysosomes opens the possibility for delivery of antigens to the cytosol and inducing the MHC class I antigen presentation pathway. [ 18 , 19 ] We next investigated the activity of FGK-LPSiNPs added to B cells, by measuring the expression of cell surface molecules indicative of B cell activation. The nanoparticles in this experiment contained avidin labeled with fl uorescein isothiocyanate (av-FITC). The resulting construct emits both in the green (from the FITC label) and in the near-infrared (from the silicon nanostructure) when excited with ultraviolet light ( Figure 3 a) . B cells enriched from mouse splenocytes were incubated with FGKLPSiNPs or av-LPSiNPs and then analyzed by fl ow cytometry. Nanoparticle characterization : Transmission electron micrographs (TEM) were obtained with a FEI Tecnai G 2 Sphera. Dynamic light scattering (Zetasizer Nano ZS90, Malvern Instruments) was used to determine the hydrodynamic size of the nanoparticles. The photoluminescence (PL, λ ex = 370 nm and 460 nm long pass emission fi lter) spectra of LPSiNP or FGK-LPSiNP were obtained using a Princeton Instruments/Acton spectrometer fi tted with a liquid nitrogencooled silicon charge-coupled device (CCD) detector. Quantifi cation of FGK45 loaded on the nanoparticles was determined by bicinchoninic acid protein assay (Micro BCA, Thermo Fisher Scientifi c, Inc.) using a subtraction method. In a typical experiment, av-LPSiNPs (0.2 mg mL − 1 ) in 1 mL water were mixed with an aliquot (0.045 mL) of water containing 0.022 mg of biotin-conjugated FGK45. The mixture was stirred for 1 h at room temperature and rinsed with water three times by centrifugation. The supernatant of each rinse was collected and the excess FGK45 in the supernatant was quantifi ed by Micro BCA assay following the manufacturer's instructions. The loading of FGK45 on the nanoparticles was calculated by subtracting the excess of FGK45 from the total quantity used for the loading experiment.
In vitro degradation of FGK-LPSiNP : A set of microtubes (typically 24 individual microtubes for a given experiment), each containing FGKLPSiNP (0.05 mg mL − 1 ) in 1 mL of PBS solution or pH 4.0 buffer solution were incubated at 37 ºC. Three microtubes (triplicate measurements) were assayed for each time point. An aliquot (0.5 mL) of solution was removed from each microtube and fi ltered with a centrifugal fi lter (30,000 Da molecular weight cut-off, Millipore, Inc.) to remove undissolved LPSiNP. 0.4 mL of the fi ltered solution was then diluted with 5 mL HNO 3 (2%(v/v)) and subjected to analysis by inductively coupled plasma optical emission spectroscopy (ICP-OES, Perkin Elmer Optima 3000DV). In order to quantify percent degradation, we assumed the nanoparticles fully dissolved in 72 h at 37 ° C in PBS buffer (pH = 7.4), and used this timepoint to determine the 100% degradation level in the ICP-OES experiments. The decrease in PL of the above samples over time was also monitored, following a previously described method. [ 1 ] Mice : C57BL/6 mice were maintained in specifi c pathogen-free facilities at the University of California, San Diego. Animal protocols were approved by the Institutional Animal Care and Use Committee.
Cell uptake of FGK-LPSiNP : Mouse bone marrow-derived dendritic cells (BMDC) were prepared as described [67] and harvested on day 8 for use in microscopy experiments. BMDC (40,000-60,000 cells per well) were seeded into 8-well chamber glass slides (Millipore, Inc.) and cultured overnight. The cells were washed with RPMI (Roswell Park Memorial Institute) medium once and incubated with 0.05 mg mL
LPSiNP or FGK-LPSiNP in RPMI medium for 1.5 h at 37 ° C. For the competitive binding experiment, BMDC were fi rst incubated with free FGK45 (0.03 mg ml − 1 ) for 30 min in RPMI medium, then incubated with FGK-LPSiNP (0.05 mg mL − 1 ) as above. The cells were washed 3 times with RPMI medium and incubated with Alexa Fluor 488 conjugated CD11c antibody (clone N418, eBioscience-all antibodies are from eBioscience unless otherwise indicated; 1 μ g ml − 1 ) in RPMI medium for 10 min to visualize the BMDC. The cells were then rinsed three times with PBS, fi xed with 4% paraformaldehyde for 20 min and then observed with a Zeiss LSM 510 confocal fl uorescence microscope. An excitation wavelength of 405 nm and an emission fi lter with a bandpass at 700 ± 50 nm were used to image the near-IR photoluminescence of the nanoparticles.
In vitro stimulation of B cells : Single-cell suspensions of C57BL/6 splenocytes were prepared and subjected to red blood cell lysis using ACK lysis buffer (0.15 M NH 4 Cl, 1 mM KHCO 3 , 0.1 mM EDTA, pH 7. Figure S6 ). This suggests that the amplifi cation induced by the FGK-LPSiNP construct results from enhancement of the agonistic antibody's intrinsic function rather than an immune response to the nanomaterial itself. The very low stimulation of APCs by LPSiNPs that do not contain FGK45 is attributed to their primarily inorganic chemical composition; the chemical structure of the silicon-based nanoparticles (and their biodegradation products) possess little similarity to natural pathogens or other "danger signals" normally presented to the immune system. [ 8 , 21 , 64 ] The present study represents the fi rst example of amplification of the potency of an agonistic CD40 mAb to stimulate APCs using nanomaterials. Agonistic CD40 mAb has attracted considerable interest [ 48 , 49 , 55 ] as it has recently entered clinical trials as a therapeutic for solid tumors. [ 46 ] The amplifi cation effect seen in the present study suggests that a nanoparticlebased CD40 antibody therapeutic may amplify the potency and decrease the dose required in the clinical application of CD40 mAb. The nanoparticle formulation may also provide a means of targeting specifi c types of immune cells by attaching additional targeting ligands on the surface of FGK-LPSiNPs. In addition to the enhancement effect, the inert inorganic composition and biodegradable property of LPSiNPs could overcome some of the disadvantages of lipid or polymer-based materials for immunotherapy applications. Their intrinsic photoluminescence can also be used to monitor the degradation of LPSiNPs and track their interaction with the immune system.
Experimental Section
Preparation of FGK45 loaded luminescent porous silicon nanoparticles (FGK-LPSiNPs) : LPSiNPs were fi rst prepared using a previously described method. [ 1 , 66 ] In brief, (100)-oriented p-type single-crystal Si wafers (0.8-1.2 m Ω cm, Siltronix) were electrochemically etched in an electrolyte containing aqueous 48% hydrofl uoric acid and ethanol in a 3:1 ratio. The resulting porous Si fi lms were lifted from the Si substrate, fractured by ultrasound and fi ltered through a 0.22 μ m membrane (Millipore, Inc). Finally, the photoluminescence of the nanoparticles were activated by soaking in deionized water for 14 d. To prepare FGK-LPSiNP, an avidin coating was fi rst applied. An aliquot (1 mL) of an aqueous dispersion of LPSiNP (0.2 mg) was mixed with an aliquot (0.08 mL) of water containing 0.04 mg of avidin (Thermo Fisher Scientifi c, Inc.). The mixture was stirred for 1 h at room temperature, rinsed with water three times by centrifugation. The particles were resuspended in water to 0.2 mg mL − 1 and were then mixed with an aliquot (0.045 mL) of water containing 0.022 mg of biotin-conjugated FGK45 (Enzo Life Sciences, Inc.; FGK45 is a monoclonal antibody to mouse CD40). The mixture was stirred for 1 h at room temperature, rinsed with water three times by centrifugation to remove any excess FGK45. The supernatant of each wash was combined and the quantity of excess FGK45 in the supernatant was measured by
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